KR102569081B1 - 락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태 - Google Patents

락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태 Download PDF

Info

Publication number
KR102569081B1
KR102569081B1 KR1020207031617A KR20207031617A KR102569081B1 KR 102569081 B1 KR102569081 B1 KR 102569081B1 KR 1020207031617 A KR1020207031617 A KR 1020207031617A KR 20207031617 A KR20207031617 A KR 20207031617A KR 102569081 B1 KR102569081 B1 KR 102569081B1
Authority
KR
South Korea
Prior art keywords
lactitol
pharmaceutical composition
liver
oral dosage
fatty liver
Prior art date
Application number
KR1020207031617A
Other languages
English (en)
Korean (ko)
Other versions
KR20200140326A (ko
Inventor
블라디미르 빅토로비치 네스테루크
키릴 콘스탠티노비치 시로브
Original Assignee
엘티디＂발렌타-인텔렉트＂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘티디＂발렌타-인텔렉트＂ filed Critical 엘티디＂발렌타-인텔렉트＂
Publication of KR20200140326A publication Critical patent/KR20200140326A/ko
Application granted granted Critical
Publication of KR102569081B1 publication Critical patent/KR102569081B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207031617A 2018-04-03 2019-03-13 락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태 KR102569081B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018111985A RU2692243C1 (ru) 2018-04-03 2018-04-03 Применение лактитола и пероральная лекарственная форма для лечения и профилактики неалкогольной жировой болезни печени
RU2018111985 2018-04-03
PCT/RU2019/000157 WO2019194703A1 (ru) 2018-04-03 2019-03-13 Лактитол и пероральная лекарственная форма при неалкогольной жировой болезни печени

Publications (2)

Publication Number Publication Date
KR20200140326A KR20200140326A (ko) 2020-12-15
KR102569081B1 true KR102569081B1 (ko) 2023-08-23

Family

ID=67038280

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031617A KR102569081B1 (ko) 2018-04-03 2019-03-13 락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태

Country Status (5)

Country Link
KR (1) KR102569081B1 (ru)
CN (1) CN111936148B (ru)
EA (1) EA202092349A1 (ru)
RU (1) RU2692243C1 (ru)
WO (1) WO2019194703A1 (ru)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2113998B (en) * 1982-02-05 1985-08-29 Cv Chemie Combinatie Amsterdam Lactitol for the treatment of liver disease
AU2001222369A1 (en) * 2000-11-17 2002-05-27 Purac Biochem B.V. Use of lactitol for improving intestinal microflora

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Francesco Salerno et al. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. Regular paper. v.21(6) pp.1092-1096 (1993.12.30.)*

Also Published As

Publication number Publication date
KR20200140326A (ko) 2020-12-15
RU2692243C1 (ru) 2019-06-24
WO2019194703A1 (ru) 2019-10-10
CN111936148A (zh) 2020-11-13
EA202092349A1 (ru) 2020-12-22
CN111936148B (zh) 2023-07-14

Similar Documents

Publication Publication Date Title
Habib et al. Hypolipidemic effect of Smallanthus sonchifolius (yacon) roots on diabetic rats: Biochemical approach
JP5342644B2 (ja) 血糖増加を制御する組成物
EP2797606A2 (en) Composition and use of a formulation to increase the ratio of gastrointestinal microbiota in phylum bacteriodites to microbiota of firmuctes phylum
US20140378543A1 (en) Methods of producing and using nutritional and pharmaceutical compositions that include one or more active substances
KR20130041902A (ko) 성인 폴리글루코산체병（ａｐｂｄ）의 치료를 위한 트리헵타노인 식이
JP2022180477A (ja) 特に、ヒトおよび動物の代謝障害の予防および治療のための医薬有効成分およびその使用
Zhou et al. DHA‐enriched phosphatidylserine ameliorates high‐fat diet‐induced kidney injury in mice possibly by regulating TLR4/NF‐κB and AMPK pathways
KR102569081B1 (ko) 락티톨 및 비알코올성 지방간 질병을 위한 경구용 약제학적 형태
WO2016000637A1 (zh) 一种降血脂组合物及其应用
JP5063369B2 (ja) メグリチニド類を含有する肝臓線維化予防用医薬組成物
Mu et al. A lipid-based nanocarrier containing active vitamin D3 ameliorates NASH in mice via direct and intestine-mediated effects on liver inflammation
CN104940181B (zh) β‑羟丁酸或其药学上可接受的盐的用途
WO2022089591A1 (zh) 氨基葡萄糖在制备治疗非酒精性脂肪性药物中的应用
EA043465B1 (ru) Применение лактитола для профилактики и лечения неалкогольной жировой болезни печени
CN110448569A (zh) 一种具有止泻功效的组合物及其制备方法和其应用
CN111686239B (zh) 抗真菌化合物的应用
RU2462251C1 (ru) Способ лечения больных хроническими заболеваниями печени с латентной стадией и i степенью клинически выраженной стадии печеночной энцефалопатии
EP3804705B1 (en) Pharmaceutical composition for preventing diabetes and use thereof
US20200197471A1 (en) S. spinosum extract for treating fatty liver disease
CN110420270A (zh) 一种含有山茶油和鱼油的功能性组合物及其应用
WO2013005834A1 (ja) 高純度ｅｐａを含有する抗肥満剤
CN110141568A (zh) 一种中药组合物及其应用
Cogorno et al. Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches
KR101572311B1 (ko) 2-아미노-2-노보네인카르복실산을 함유하는 비만 예방 또는 치료용 조성물
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right